Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
Authors
Keywords
IL-6 signaling in neoplastic plasma cells, Myeloma stem cells and minimal residual disease, Small-drug- and monoclonal antibody-based inhibitors, Genetically engineered mouse models of human myeloma
Journal
IMMUNOLOGIC RESEARCH
Volume 59, Issue 1-3, Pages 188-202
Publisher
Springer Nature
Online
2014-05-20
DOI
10.1007/s12026-014-8528-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
- (2015) Qing Chang et al. NEOPLASIA
- Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation
- (2014) Lotte Spel et al. OncoImmunology
- Tumor-associated macrophages as a prognostic parameter in multiple myeloma
- (2013) Elif Suyanı et al. ANNALS OF HEMATOLOGY
- Pursuing the curative blueprint for early myeloma
- (2013) M. Roschewski et al. BLOOD
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
- (2013) M. Casucci et al. BLOOD
- Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells
- (2013) T. Tanno et al. BLOOD
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
- (2013) G. T. Gorgun et al. BLOOD
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients
- (2013) Willemijn Hobo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
- (2013) J. Rosenblatt et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Macrophages in multiple myeloma
- (2013) Domenico Ribatti et al. IMMUNOLOGY LETTERS
- Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
- (2013) Marco L. Davila et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Constitutive Activation of Signal Transducer and Activator of Transcription 3 (STAT3) and Nuclear Factor κB Signaling in Glioblastoma Cancer Stem Cells Regulates the Notch Pathway
- (2013) Jo Meagan Garner et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Minimal Residual Disease in Multiple Myeloma
- (2013) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokines driving breast cancer stemness
- (2013) Andrew R. Chin et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Induction of Malignant Plasma Cell Proliferation by Eosinophils
- (2013) Tina W. Wong et al. PLoS One
- Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
- (2013) Lihua E. Budde et al. PLoS One
- Impact of Interleukin-6 in Hematological Malignancies
- (2013) Renate Burger TRANSFUSION MEDICINE AND HEMOTHERAPY
- 18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib
- (2013) K Duncan et al. Blood Cancer Journal
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance
- (2013) C Bryant et al. Blood Cancer Journal
- Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell Hypothesis
- (2012) Jasmin Agarwal et al. Anti-Cancer Agents in Medicinal Chemistry
- STAT3 & Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells
- (2012) Sun Jung Myung et al. BIOMEDICINE & PHARMACOTHERAPY
- Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
- (2012) B. A. Walker et al. BLOOD
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice
- (2012) J. Suthaus et al. BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
- (2012) K Giannopoulos et al. BRITISH JOURNAL OF CANCER
- Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
- (2012) Jaehyup Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
- (2012) K. Boucher et al. CLINICAL CANCER RESEARCH
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model
- (2012) E Van Valckenborgh et al. LEUKEMIA
- PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma
- (2012) Y Zheng et al. LEUKEMIA
- Latest advances and current challenges in the treatment of multiple myeloma
- (2012) Anuj Mahindra et al. Nature Reviews Clinical Oncology
- Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
- (2012) Karthick Raja Muthu Raja et al. PLoS One
- Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment
- (2012) Karthick Raja Muthu Raja et al. PLoS One
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells
- (2011) Li Lin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells
- (2011) L. Lin et al. CANCER RESEARCH
- Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer
- (2011) Marie Tosolini et al. CANCER RESEARCH
- Simultaneous inhibition of the constitutively activated nuclear factor κB and of the Interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells
- (2011) Natalia Malara et al. CELL CYCLE
- The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells
- (2011) L. Lopez-Corral et al. CLINICAL CANCER RESEARCH
- T regulatory cells in B-cell malignancy - tumour support or kiss of death?
- (2011) Camilla A. Lindqvist et al. IMMUNOLOGY
- The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
- (2011) K A Monaghan et al. LEUKEMIA
- Eosinophils are required for the maintenance of plasma cells in the bone marrow
- (2011) Van Trung Chu et al. NATURE IMMUNOLOGY
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
- (2010) J. Rosenblatt et al. BLOOD
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
- (2010) R. H. Prabhala et al. BLOOD
- Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma
- (2010) Jaroslav Michalek et al. BRITISH JOURNAL OF HAEMATOLOGY
- Regulatory T cells and breast cancer: implications for immunopathogenesis
- (2010) Maria Angelica Ehara Watanabe et al. CANCER AND METASTASIS REVIEWS
- IL-6: from its discovery to clinical applications
- (2010) T. Kishimoto INTERNATIONAL IMMUNOLOGY
- The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
- (2010) A Scuto et al. LEUKEMIA
- Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
- (2010) M. K. Brimnes et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- IL-6 and MYC collaborate in plasma cell tumor formation in mice
- (2009) S. Rutsch et al. BLOOD
- Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma
- (2009) V. Racanelli et al. BLOOD
- A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
- (2009) M. Fulciniti et al. CLINICAL CANCER RESEARCH
- T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
- (2009) Natalia Martin-Orozco et al. IMMUNITY
- Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
- (2009) R. Burger et al. MOLECULAR CANCER THERAPEUTICS
- Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells
- (2008) Juwon Park et al. ANTI-CANCER DRUGS
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
- (2008) Y. Okawa et al. BLOOD
- Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma
- (2008) K. M. Dhodapkar et al. BLOOD
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- Peroxisome Proliferator-Activated Receptor Overexpression Suppresses Growth and Induces Apoptosis in Human Multiple Myeloma Cells
- (2008) T. M. Garcia-Bates et al. CLINICAL CANCER RESEARCH
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation
- (2008) D. Atanackovic et al. HAEMATOLOGICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started